Gemcitabine: Progress in the Treatment of Pancreatic Cancer

Publisher： Karger

E-ISSN： 1423-0232|60|1|8-18

ISSN： 0030-2414

Source： Oncology, Vol.60, Iss.1, 2000-12, pp. : 8-18

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

“Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK”: How important is quality of life?

By Bansback Nick   Ward Sue   Karnon Jon  

The European Journal of Health Economics, Vol. 5, Iss. 2, 2004-05 ,pp. : 188-189

Springer Publishing Company

Access to resources Recommend Favorite

Do Recurrent and Metastatic Pancreatic Cancer Patients Have the Same Outcomes with Gemcitabine Treatment?

By  

Oncology, Vol. 77, Iss. 3-4, 2009-09 ,pp. : 217-223

Karger

Access to resources Recommend Favorite

Sustained Partial Remission of Metastatic Pancreatic Cancer Following Systemic Chemotherapy with Gemcitabine and Oxaliplatin plus Adjunctive Treatment with Mistletoe Extract

By  

Oncology Research and Treatment, Vol. 33, Iss. 11, 2010-10 ,pp. : 617-619

Karger

Access to resources Recommend Favorite

Patients with Advanced Pancreatic Cancer and Hyperbilirubinaemia: Review and German Expert Opinion on Treatment with nab-Paclitaxel plus Gemcitabine

By  

Oncology Research and Treatment, Vol. 38, Iss. 11, 2015-0 ,pp. : 596-603

Karger

Access to resources Recommend Favorite

Gemcitabine Plus Nab-Paclitaxel as Second-Line and Beyond Treatment for Metastatic Pancreatic Cancer: a Single Institution Retrospective Analysis

By  

Reviews on Recent Clinical Trials, Vol. 10, Iss. 2, 2015-01 ,pp. : 142-145

Bentham Science Publishers

Access to resources Recommend Favorite